© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 4, 302-303,
February 17, 1999
© 1999 Oxford University Press
EDITORIALS |
Current Status of Sentinel Lymph Node Surgery for Breast Cancer
Correspondence to: David Krag, M.D., Department of Surgery, University of Vermont, E309 Given Bldg., Burlington, VT 05405.
In 1997, Veronesi et al. (1) reported in the Lancet on their sentinel lymph node experience in a series of 163 patients with breast cancer. The day before surgery, a small volume of colloidal human albumin labeled with technetium 99m was injected subdermally over the tumor in these patients. Gamma camera imaging was performed, and a hand-held gamma probe was used to guide the surgical resection of the sentinel nodes (SNs). The use of blue dye was not reported. In 98% of the cases, at least one SN could be identified surgically. The false-negative rate (i.e., number of cases with negative SNs but positive non-SNs x 100/total number of cases with positive nodes) was 5%. The overall accuracy was 98%. Frozen section analysis had a higher false-negative rate of 36%.
Now, this group from Milan reports in this issue of the Journal on 376
cases (i.e., the 163
COMPREHENSIVE DETECTION OF SNS
COMPLETE STAGING OF LYMPH NODES
REGIONAL CONTROL AND SURVIVAL
INTRAOPERATIVE PATHOLOGY
PREVIOUS EXCISIONAL BIOPSY
METHOD OF TRACER INJECTION
GAMMA CAMERA IMAGING
RADIATION EXPOSURE
NOTES
REFERENCES